PAXLOVID

Nov. 8, 2021

Pfizer announced trial results for its investigational Covid-19 oral antiviral candidate, Paxlovid, saying it significantly reduced hospitalisation and death.

About:

It is an investigational SARS-CoV-2 “protease inhibitor antiviral therapy”.
It inhibits viral replication at proteolysis, a stage that occurs before viral replication.
It is “designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure, potentially helping patients avoid severe illness.”
Pfizer said it has entered into advance purchase agreements with “multiple countries and is in negotiations with several others”.

Source : Indian Express

Latest Current Affairs

See All

State of the Climate 2024 Report

State of the Climate 2024 Report once...

Nov. 14, 2024 Environment

What is the Wildlife Institute of India (WII)?

Experts from the Wildlife Institute o...

Nov. 14, 2024 Environment

What is Walking Pneumonia?

In recent weeks, doctors have reporte...

Nov. 14, 2024 Science & Tech

What is Crinum andhricum?

Botanists recently discovered a new s...

Nov. 14, 2024 Environment

Sukhna Lake

The Union Ministry of Environment, Fo...

Nov. 14, 2024 Geography

Exercise Sea Vigil

The Indian Navy is set to conduct the...

Nov. 14, 2024 Science & Tech

Cardiovascular Kidney Metabolic Syndrome

An unhealthy lifestyle and the influe...

Nov. 14, 2024 Science & Tech

Amorphophallus Titanum

People in Geelong city have beelined ...

Nov. 14, 2024 Environment

World Intellectual Property Indicators

The World Intellectual Property Organ...

Nov. 14, 2024 Economy

Booker Prize

British writer Samantha Harvey won th...

Nov. 14, 2024 Polity & Governance